Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
about
New criteria for response assessment: role of minimal residual disease in multiple myelomaAssessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.Immunophenotypic studies of monoclonal gammopathy of undetermined significanceFlow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Dilemmas in treating smoldering multiple myeloma.Bone marrow immunohistology of plasma cell neoplasms.A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.Molecular monitoring of minimal residual disease in patients with multiple myeloma.Future directions in multiple myeloma treatment.Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.Flow-cytometric immunophenotyping of normal and malignant lymphocytes.Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Immunophenotyping in multiple myeloma and related plasma cell disorders.Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myelomaImmunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsMultiple Myeloma Minimal Residual Disease.Mechanisms of Resistance in Multiple Myeloma.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.Standardisation of minimal residual disease in multiple myeloma.Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis.Assessment of minimal residual disease in myeloma and the need for a consensus approach.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myelomaDetection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.Current applications of multiparameter flow cytometry in plasma cell disorders.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).
P2860
Q27027512-D7963EA0-D189-47F9-89E0-193CFE23BA80Q33294938-A2EBD709-D67F-4D20-9B1B-268074684DFEQ33387979-3CE332EB-17A2-4FA1-874B-DF00D6AE474AQ33602593-5512F1DA-FB8F-485D-B047-8C366245DB6FQ34716500-9C7852CD-32DC-4BA2-B99F-530716802512Q35144166-07329F26-242C-4EBA-9B2C-E9FE339616CFQ35573416-2A8927CD-395D-4EF5-B0FB-A2ED6AF05363Q35668677-AD616858-E49C-4E37-A7DF-1E3B8BB4BBCAQ36258701-79FF7E84-B344-4E7A-B846-480990997C02Q36376043-7957B38D-C22B-4AE6-99C8-013749D1E0DFQ36507615-C6CD77B1-9E77-43CE-8138-CF05C597B273Q36872779-48DCC1F3-280F-474A-93C1-61E796AED0AFQ36969778-36537F1C-F371-47DA-9086-D0FD6C98FE49Q37812870-D65EE56D-CE15-4A2A-B9E8-CC0427D40216Q38059720-EDA0E725-7DA1-4C20-9FE3-81C819328E14Q38133611-67A0C4AA-5287-411B-B460-D7E8BBC81644Q38219408-BB5BBADA-EAD4-41F2-B58F-60C8DB2670EEQ38534837-1A3B3780-3376-4CF9-B7C7-3A9F2D978ACCQ38543115-65B73C9B-3180-4282-B520-75ACCA536D21Q38543122-A40BC091-D589-4E29-A6F1-9C45C8DE9B81Q38789282-DD8B008D-8B3D-45E3-8DAE-3F14F72DBB79Q38970590-FC70B160-A14B-4AFF-8E62-26AF32E6A122Q39185604-E2A76105-E0B7-4368-8AAF-7AA76DAB654BQ39386287-C5CE8436-7376-40E8-8E60-E33CA360D337Q39410899-092BB1EB-C152-4DAF-9410-6EB2038E61C7Q39743541-6DCFDEDA-5B4B-483F-9B73-E04F423081D8Q40469944-7E8826BC-0017-4132-8849-E0E35ED75CA7Q41007930-4C1DEF12-FD5E-4139-91DE-C7485489B832Q41556524-0A4EE9EF-7741-4EC8-A55E-862F3821ADE5Q42050819-A3D4C193-EE81-474A-A68A-BCBCACE42C61Q42186017-860E7C6F-FCD8-4F03-A807-48F28130186BQ43100815-DE2B2B8A-E908-4DED-9239-2ADE3DCAE492Q44510116-D0FA74AB-8244-40D1-BE33-F8C9B7F6CF54Q45287020-99E8DDA4-1A10-410D-BBC7-C29311EA0244Q47110039-74370C74-E490-408F-9E4A-067DF8A3F5B4Q47996009-5DEBD967-26F9-4BA0-9F61-E5D88591AAE0Q49114034-01F0B260-7497-4FCB-9582-CB152F94DC89Q49641900-67D5B9AA-6C8A-46E6-BF48-0EFA74E23112Q50539011-5D8F4B97-7626-4B55-A15B-DD6E912188DDQ52852076-C1B7B8A1-AF69-4CA3-8EF8-B3215A3357E9
P2860
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Flow cytometric disease monito ...... outcome after transplantation.
@en
Flow cytometric disease monito ...... outcome after transplantation.
@en-gb
Flow cytometric disease monito ...... outcome after transplantation.
@nl
type
label
Flow cytometric disease monito ...... outcome after transplantation.
@en
Flow cytometric disease monito ...... outcome after transplantation.
@en-gb
Flow cytometric disease monito ...... outcome after transplantation.
@nl
prefLabel
Flow cytometric disease monito ...... outcome after transplantation.
@en
Flow cytometric disease monito ...... outcome after transplantation.
@en-gb
Flow cytometric disease monito ...... outcome after transplantation.
@nl
P2093
P1433
P1476
Flow cytometric disease monito ...... outcome after transplantation.
@en
P2093
A John Ashcroft
Andrew S Jack
Faith E Davies
J Anthony Child
Mark T Drayson
Ranjit DasGupta
Roger G Owen
Russell Patmore
P304
P356
10.1182/BLOOD-2001-12-0297
P407
P577
2002-11-01T00:00:00Z